|Bid||60.70 x 1200|
|Ask||63.95 x 800|
|Day's range||62.16 - 64.39|
|52-week range||55.07 - 137.61|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||8.76|
|Earnings date||29 Jul 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.17|
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not Emergent BioSolutions can recover from its recent blunders. Brian Orelli: Yes, they can fix the issues that they had with the manufacturing and get better management in there to make sure that they're following all the FDA rules and good manufacturing practices.
Johnson & Johnson (NYSE: JNJ) hasn't become the major player in the COVID-19 vaccine market that many expected it to be, in large part because of manufacturing issues at a contractor's facility. Now, those issues have become even worse, and the Food and Drug Administration has told the healthcare giant that it must discard 60 million doses of its COVID-19 vaccine. In this Motley Fool Live video recorded on June 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why J&J is having to dump these vaccine doses.